Walter M. Stadler to Methotrexate
This is a "connection" page, showing publications Walter M. Stadler has written about Methotrexate.
Connection Strength
0.568
-
Treatment of metastatic urothelial cancer in the post-MVAC era. World J Urol. 2001 Apr; 19(2):126-32.
Score: 0.188
-
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
Score: 0.124
-
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
Score: 0.096
-
Gemcitabine doublets in advanced urothelial cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 3):15-9.
Score: 0.050
-
[New chemotherapy regimens for advanced bladder cancer]. Actas Urol Esp. 1998 Jun; 22(6):548-9.
Score: 0.039
-
New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol. 1998 Feb; 16(1):23-9.
Score: 0.038
-
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int. 2008 Nov; 102(9 Pt B):1339-44.
Score: 0.020
-
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol. 2005 Apr; 28(2):109-13.
Score: 0.015